This company has been marked as potentially delisted and may not be actively trading. Boundless Bio (BOLD) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock BOLD vs. NLTX, CYBN, LRMR, PBYI, NVCT, ELDN, SNSE, SPRO, SLN, and LFVNShould you be buying Boundless Bio stock or one of its competitors? The main competitors of Boundless Bio include Neoleukin Therapeutics (NLTX), Cybin (CYBN), Larimar Therapeutics (LRMR), Puma Biotechnology (PBYI), Nuvectis Pharma (NVCT), Eledon Pharmaceuticals (ELDN), Sensei Biotherapeutics (SNSE), Spero Therapeutics (SPRO), Silence Therapeutics (SLN), and LifeVantage (LFVN). These companies are all part of the "medical" sector. Boundless Bio vs. Its Competitors Neoleukin Therapeutics Cybin Larimar Therapeutics Puma Biotechnology Nuvectis Pharma Eledon Pharmaceuticals Sensei Biotherapeutics Spero Therapeutics Silence Therapeutics LifeVantage Neoleukin Therapeutics (NASDAQ:NLTX) and Boundless Bio (NASDAQ:BOLD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment, risk and valuation. Does the MarketBeat Community favor NLTX or BOLD? Boundless Bio received 421 more outperform votes than Neoleukin Therapeutics when rated by MarketBeat users. Likewise, 68.96% of users gave Boundless Bio an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote. CompanyUnderperformOutperformNeoleukin TherapeuticsOutperform Votes5045.87% Underperform Votes5954.13% Boundless BioOutperform Votes47168.96% Underperform Votes21231.04% Does the media prefer NLTX or BOLD? In the previous week, Neoleukin Therapeutics' average media sentiment score of 0.00 equaled Boundless Bio'saverage media sentiment score. Company Overall Sentiment Neoleukin Therapeutics Neutral Boundless Bio Neutral Do analysts recommend NLTX or BOLD? Boundless Bio has a consensus price target of $4.00, suggesting a potential upside of 284.62%. Given Boundless Bio's stronger consensus rating and higher probable upside, analysts clearly believe Boundless Bio is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Boundless Bio 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has more risk and volatility, NLTX or BOLD? Neoleukin Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Boundless Bio has a beta of -1.57, indicating that its share price is 257% less volatile than the S&P 500. Which has higher valuation & earnings, NLTX or BOLD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-5.88Boundless BioN/AN/A-$65.36MN/AN/A Do institutionals & insiders hold more shares of NLTX or BOLD? 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by insiders. Comparatively, 21.1% of Boundless Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is NLTX or BOLD more profitable? Neoleukin Therapeutics' return on equity of -37.22% beat Boundless Bio's return on equity.Company Net Margins Return on Equity Return on Assets Neoleukin TherapeuticsN/A -37.22% -30.91% Boundless Bio N/A -41.60%-34.53% SummaryBoundless Bio beats Neoleukin Therapeutics on 6 of the 11 factors compared between the two stocks. Get Boundless Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BOLD vs. The Competition Export to ExcelMetricBoundless BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.28M$66.29M$5.15B$8.53BDividend YieldN/AN/A5.36%4.19%P/E RatioN/AN/A25.5119.13Price / SalesN/AN/A411.68116.13Price / CashN/AN/A35.5255.99Price / Book0.150.957.975.79Net Income-$65.36M-$26.57M$3.15B$248.81M Boundless Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BOLDBoundless Bio2.8784 of 5 stars$1.04-54.8%$4.00+284.6%-82.4%$23.28MN/A0.00207Gap UpNLTXNeoleukin TherapeuticsN/A$18.97-4.0%N/A-39.6%$178.28MN/A-6.1090High Trading VolumeCYBNCybin2.405 of 5 stars$7.71-4.1%$86.00+1,015.4%N/A$176.94MN/A-1.7650LRMRLarimar Therapeutics2.9651 of 5 stars$2.69-6.9%$19.67+631.1%-65.2%$172.24MN/A-2.3430Positive NewsPBYIPuma Biotechnology4.0638 of 5 stars$3.43-0.6%$7.00+104.1%+10.0%$170.23M$232.71M7.15200Gap UpNVCTNuvectis Pharma2.6136 of 5 stars$8.11-6.1%$17.00+109.6%+24.8%$169.45MN/A-6.998News CoverageInsider TradeELDNEledon Pharmaceuticals2.747 of 5 stars$2.81+0.4%$12.50+344.8%+6.5%$168.27MN/A-1.4010Analyst UpgradeAnalyst RevisionSNSESensei Biotherapeutics4.5341 of 5 stars$6.55+0.5%$90.00+1,274.0%-36.8%$165.11MN/A-5.5040Stock SplitGap UpSPROSpero Therapeutics3.5832 of 5 stars$2.90+1.8%$5.00+72.4%+131.5%$162.14M$28.30M41.43150SLNSilence Therapeutics2.8361 of 5 stars$5.37+6.1%$33.83+530.0%-70.1%$160.72M$27.70M-3.42100Gap UpLFVNLifeVantage3.9649 of 5 stars$12.70-0.5%$30.50+140.2%+88.8%$159.87M$222.35M22.68260 Related Companies and Tools Related Companies Neoleukin Therapeutics Competitors Cybin Competitors Larimar Therapeutics Competitors Puma Biotechnology Competitors Nuvectis Pharma Competitors Eledon Pharmaceuticals Competitors Sensei Biotherapeutics Competitors Spero Therapeutics Competitors Silence Therapeutics Competitors LifeVantage Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BOLD) was last updated on 6/20/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe Biggest Story of My Decade-Long Career in Silicon ValleySteve Jobs' Lost 'Product' Could Save Tesla On July 21st, a revolutionary announcement could transform Tesl...InvestorPlace | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Boundless Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Boundless Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
